Blake Borgeson - Aug 8, 2023 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Director
Signature
/s/ Jonathan Golightly, attorney-in-fact
Stock symbol
RXRX
Transactions as of
Aug 8, 2023
Transactions value $
-$198,283
Form type
4
Date filed
8/10/2023, 05:33 PM
Previous filing
Jul 13, 2023
Next filing
Aug 24, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Sale -$160K -14.5K -0.19% $11.03 7.47M Aug 8, 2023 Direct F1, F2
transaction RXRX Class A Common Stock Sale -$38.4K -3.27K -0.04% $11.75 7.47M Aug 8, 2023 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022.
F2 The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $10.62 to $11.60 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
F3 The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $11.62 to $11.93 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.